In Canada, Zepbound is approved as a long-term treatment for adults with obesity (BMI 30), or those who are overweight (BMI 27) and living with at least one weight-related health condition (including hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease)
Doctors believe that semaglutide does not directly weaken the lower esophageal sphincter (LES), which is the muscle that prevents stomach acid from coming up
The medication works continuously as long as you take it
Front-loading protein is critical when appetite is suppressed
One of the most common demyelinating diseases is multiple sclerosis (MS)
However, Canadian researchers can access Retatrutide through research peptide suppliers who ship domestically